Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

EU research funding programme may not support embryonic stem cell research

08 October 2012

By Tom Barrow

Appeared in BioNews 676

The future funding of human embryonic stem cell (hESC) research under the European Union (EU) may be in jeopardy after its inclusion in the next research funding programme is challenged by MEPs.

A Nature News blog reports the European Parliament's Legal Affairs Committee voted to exclude hESC research from Horizon 2020, the EU research and innovation programme due to run from 2014, citing the contentious decision by the European Court of Justice (ECJ) prohibiting the granting of patents for processes that involve the destruction of embryos at any stage.

The Committee said if hESC research cannot be patented under European law, then it could not contribute to economic competitiveness and should not be funded by Horizon 2020. Patents are required to help stimulate EU competition, which is one of the intended functions of the funding programme.

In the draft proposals of Horizon 2020, the €80 billion programme would finance stem cell research including hESC research, which is allowed under the current programme. However, four pro-life MEPs, who do not agree with public funds contributing to such research, have indicated that they intend to challenge the legality of Horizon 2020 for its inclusion of hESC research.

Peter Liese, an MEP from Germany who opposes the programme, was quoted in Europolitics as saying: 'We reject harmonisation of national regulations on this sensitive issue in Europe'. Two key issues that opponents of Horizon 2020 intend to address are the patentability of hESC research and how projects currently under way are to be funded.

The ECJ judgment forms a focal point for the argument against the programme, as Professor Klaus Gärditz of the University of Bonn in Germany submits. He told Europolitics that 'life cannot be taken away to be marketed'.

'Human dignity...is a primary right', he said. 'Research on embryonic stem cells must therefore be excluded by substantive law. If certain prohibited areas are subsidised, the entire framework programme is in danger. The risk to European research is huge'.

Supporters of hESC under the Horizon 2020 programme argue that the research is essential for the development of treatments for disorders such as Alzheimer's disease, Parkinson's disease and motor neurone disease. It is also argued that alternatives to hESC research, such as using induced pluripotent stem cells or adult stem cells, are insufficient methods in comparison. Fundamentally, those in favour of hESC research say that cell lines used are obtained from IVF clinics, and would otherwise be destroyed.

The UK and Europe are at the pinnacle of stem cell research, says Professor Peter Weissberg, medical director at the British Heart Foundation, who argues that 'any scaling back of the EU's investment would send out a dangerous message that could seriously damage this area of research in Europe, to the detriment of patients in the future'.

Sir Mark Walport, director of the Wellcome Trust, in an earlier joint statement urging funding of hESC research in Europe, said: 'The European Parliament must send a clear sign that it recognises the importance of [hESC] research...to close down such a vital avenue of research would be a massive blow to European science'.

'It will significantly set back research into very serious diseases including Parkinson's and multiple sclerosis and is likely to cost European research its competitive advantage', he added.

Whether Horizon 2020, as it stands, is to be advanced or rejected needs to be decided by the EU's Parliament and Council by the end of 2013.

SOURCES & REFERENCES
Nature News | 26 September 2012
 
Europolitics | 12 September 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

02 June 2014 - by Patricia Cassidy 
The European Commission has rejected a petition requesting a stop to the funding of research involving the 'presupposed destruction' of human embryos....
14 January 2013 - by Sarah Pritchard 
The US Supreme Court has declined to hear a final appeal seeking to challenge the legality of using public money to fund embryonic stem cell (hESC) research...
17 December 2012 - by Julian Hitchcock 
In November the case of Brüstle v Greenpeace was remitted to the German Federal High Court. How would a national court interpret the controversial ruling of the Court of Justice of the European Union which held that patent rights could not be granted in the EU for the use of any entity 'capable of commencing the process of development of a human being'?...
03 December 2012 - by Antony Blackburn-Starza 
The German Federal Court of Justice has ruled that a disputed patent held by Dr Oliver Brüstle, and the subject of a ruling by the European Court of Justice (ECJ) against the patentability of human embryonic stem cells, is valid in its revised form....

03 September 2012 - by Victoria Kay 
The US Court of Appeals has upheld a ruling permitting the use of federal funds for research involving human embryonic stem cells....
25 June 2012 - by Antony Blackburn-Starza 
Six major UK research funding bodies have called for the continued funding of human embryonic stem cell (hESC) research in the EU's programme for research and development...
31 January 2012 - by Dr Amy Strange 
The recent ruling of the European Court of Justice (ECJ) excluding inventions relating to human embryonic stem cells (ES cells) from patentability has sparked a heated debate in the bioscience, ethics and law communities...
19 December 2011 - by Antony Blackburn-Starza 
A survey of over 200 human embryonic stem cell (hESC) researchers in the US has found almost four in ten respondents had experienced delays in obtaining cell lines and over one-quarter said they were unable to obtain a required cell line at all....
24 October 2011 - by Antony Blackburn-Starza 
The European Court of Justice (ECJ) has ruled that stem cell processes which require the prior destruction of human embryos or are based upon the use of human embryos are not patentable. The decision may have wide implications for scientists engaged in embryonic stem cell research....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation